vs

Side-by-side financial comparison of Adtalem Global Education Inc. (ATGE) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($749.2M vs $503.4M, roughly 1.5× Adtalem Global Education Inc.). Adtalem Global Education Inc. runs the higher net margin — 15.2% vs 3.6%, a 11.5% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs 12.4%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs 10.4%).

Adtalem Global Education Inc. is a US corporation based in Chicago, Illinois, that operates for-profit higher education institutions, including American University of the Caribbean School of Medicine, Chamberlain University, Ross University School of Medicine, Ross University School of Veterinary Medicine, and Walden University.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

ATGE vs CLOV — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.5× larger
CLOV
$749.2M
$503.4M
ATGE
Growing faster (revenue YoY)
CLOV
CLOV
+49.6% gap
CLOV
62.0%
12.4%
ATGE
Higher net margin
ATGE
ATGE
11.5% more per $
ATGE
15.2%
3.6%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
10.4%
ATGE

Income Statement — Q2 FY2026 vs Q1 FY2026

Metric
ATGE
ATGE
CLOV
CLOV
Revenue
$503.4M
$749.2M
Net Profit
$76.4M
$27.3M
Gross Margin
59.2%
Operating Margin
22.1%
3.6%
Net Margin
15.2%
3.6%
Revenue YoY
12.4%
62.0%
Net Profit YoY
0.7%
EPS (diluted)
$2.11
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATGE
ATGE
CLOV
CLOV
Q1 26
$749.2M
Q4 25
$503.4M
$487.7M
Q3 25
$462.3M
$496.6M
Q2 25
$457.1M
$477.6M
Q1 25
$466.1M
$462.3M
Q4 24
$447.7M
$337.0M
Q3 24
$417.4M
$331.0M
Q2 24
$409.9M
$356.3M
Net Profit
ATGE
ATGE
CLOV
CLOV
Q1 26
$27.3M
Q4 25
$76.4M
$-49.3M
Q3 25
$61.8M
$-24.4M
Q2 25
$54.2M
$-10.6M
Q1 25
$60.8M
$-1.3M
Q4 24
$75.9M
$-22.1M
Q3 24
$46.2M
$-9.2M
Q2 24
$49.4M
$7.4M
Gross Margin
ATGE
ATGE
CLOV
CLOV
Q1 26
Q4 25
59.2%
Q3 25
56.6%
Q2 25
56.5%
Q1 25
57.1%
Q4 24
58.3%
Q3 24
55.4%
24.5%
Q2 24
55.5%
30.3%
Operating Margin
ATGE
ATGE
CLOV
CLOV
Q1 26
3.6%
Q4 25
22.1%
-10.1%
Q3 25
18.5%
-4.9%
Q2 25
16.8%
-2.2%
Q1 25
19.4%
-0.3%
Q4 24
23.2%
-6.4%
Q3 24
16.8%
-2.7%
Q2 24
16.7%
2.0%
Net Margin
ATGE
ATGE
CLOV
CLOV
Q1 26
3.6%
Q4 25
15.2%
-10.1%
Q3 25
13.4%
-4.9%
Q2 25
11.9%
-2.2%
Q1 25
13.1%
-0.3%
Q4 24
16.9%
-6.6%
Q3 24
11.1%
-2.8%
Q2 24
12.1%
2.1%
EPS (diluted)
ATGE
ATGE
CLOV
CLOV
Q1 26
$0.05
Q4 25
$2.11
Q3 25
$1.67
Q2 25
$1.43
Q1 25
$1.59
Q4 24
$1.98
Q3 24
$1.18
Q2 24
$1.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATGE
ATGE
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$56.3M
$177.6M
Total DebtLower is stronger
$504.3M
Stockholders' EquityBook value
$1.4B
$339.4M
Total Assets
$2.6B
$697.7M
Debt / EquityLower = less leverage
0.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATGE
ATGE
CLOV
CLOV
Q1 26
$177.6M
Q4 25
$56.3M
$78.3M
Q3 25
$264.7M
Q2 25
$199.6M
Q1 25
$219.0M
Q4 24
$194.0M
$194.5M
Q3 24
$264.8M
$288.0M
Q2 24
$219.3M
$254.8M
Total Debt
ATGE
ATGE
CLOV
CLOV
Q1 26
Q4 25
$504.3M
Q3 25
$553.2M
Q2 25
$552.7M
Q1 25
$552.2M
Q4 24
$649.9M
Q3 24
$649.3M
Q2 24
$648.7M
Stockholders' Equity
ATGE
ATGE
CLOV
CLOV
Q1 26
$339.4M
Q4 25
$1.4B
$308.7M
Q3 25
$1.5B
$340.9M
Q2 25
$1.4B
$344.2M
Q1 25
$1.4B
$336.1M
Q4 24
$1.4B
$341.1M
Q3 24
$1.4B
$342.2M
Q2 24
$1.4B
$324.9M
Total Assets
ATGE
ATGE
CLOV
CLOV
Q1 26
$697.7M
Q4 25
$2.6B
$541.0M
Q3 25
$2.9B
$559.7M
Q2 25
$2.8B
$575.0M
Q1 25
$2.8B
$583.7M
Q4 24
$2.7B
$580.7M
Q3 24
$2.8B
$653.0M
Q2 24
$2.7B
$674.2M
Debt / Equity
ATGE
ATGE
CLOV
CLOV
Q1 26
Q4 25
0.37×
Q3 25
0.38×
Q2 25
0.39×
Q1 25
0.39×
Q4 24
0.45×
Q3 24
0.47×
Q2 24
0.47×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATGE
ATGE
CLOV
CLOV
Operating Cash FlowLast quarter
$29.7M
Free Cash FlowOCF − Capex
$15.1M
FCF MarginFCF / Revenue
3.0%
Capex IntensityCapex / Revenue
2.9%
Cash ConversionOCF / Net Profit
0.39×
TTM Free Cash FlowTrailing 4 quarters
$368.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATGE
ATGE
CLOV
CLOV
Q1 26
Q4 25
$29.7M
$-66.9M
Q3 25
$130.5M
$12.1M
Q2 25
$59.7M
$5.4M
Q1 25
$207.9M
$-16.3M
Q4 24
$-19.0M
$34.8M
Q3 24
$89.3M
$50.0M
Q2 24
$40.6M
$44.8M
Free Cash Flow
ATGE
ATGE
CLOV
CLOV
Q1 26
Q4 25
$15.1M
$-69.0M
Q3 25
$114.5M
$11.4M
Q2 25
$40.7M
$4.8M
Q1 25
$197.7M
$-16.5M
Q4 24
$-29.7M
$33.3M
Q3 24
$78.9M
$49.6M
Q2 24
$37.4M
$44.4M
FCF Margin
ATGE
ATGE
CLOV
CLOV
Q1 26
Q4 25
3.0%
-14.1%
Q3 25
24.8%
2.3%
Q2 25
8.9%
1.0%
Q1 25
42.4%
-3.6%
Q4 24
-6.6%
9.9%
Q3 24
18.9%
15.0%
Q2 24
9.1%
12.5%
Capex Intensity
ATGE
ATGE
CLOV
CLOV
Q1 26
Q4 25
2.9%
0.4%
Q3 25
3.5%
0.1%
Q2 25
4.2%
0.1%
Q1 25
2.2%
0.0%
Q4 24
2.4%
0.5%
Q3 24
2.5%
0.1%
Q2 24
0.8%
0.1%
Cash Conversion
ATGE
ATGE
CLOV
CLOV
Q1 26
Q4 25
0.39×
Q3 25
2.11×
Q2 25
1.10×
Q1 25
3.42×
Q4 24
-0.25×
Q3 24
1.93×
Q2 24
0.82×
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ATGE
ATGE

Walden University Segment$217.6M43%
Chamberlain University Segment$183.8M37%
Medical And Veterinary$102.0M20%
Other Services$1.6M0%

CLOV
CLOV

Segment breakdown not available.

Related Comparisons